Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate mofetil and daclizumab in recently diagnosed type 1 diabetes mellitus
2005-000904-15Phase 2Completed
- Sponsor
- George Washington University Biostatistics Center
- Start
- Jul 2005
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of mycophenolate mofetil and daclizumab in diabetes mellitus type 1 (T1D), sponsored by George Washington University Biostatistics Center. Primary endpoint: Stimulated C-peptide AUC over first 2 hours of 4-hour mixed meal tolerance test at month 24. Started Jul 2005; status: completed.
02
Drugs
mycophenolate mofetildaclizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2005-000904-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000904-15.